文献速递脑血管病

新型PDE-3抑制剂独立于血小板功能保护小鼠免于缺血性卒中

Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function.
PubMed 文献 · Stroke · 2019-01-01

该研究在小鼠短暂性大脑中动脉闭塞模型中,于缺血诱导后1小时给予新型PDE-3抑制剂物质V或溶剂,评估梗死体积和功能结局至第7天。结果显示物质V显著减少梗死体积、改善神经功能,机制涉及减轻血脑屏障损伤、脑组织炎症和局部细胞死亡,且不增加脑出血或影响血小板功能。

要点

  • 新型PDE-3抑制剂物质V在小鼠脑缺血后1小时给药可减少梗死体积并改善神经功能。
  • 保护机制与减轻血脑屏障损伤、抑制脑组织炎症和减少细胞死亡相关。
  • 物质V不增加脑内出血数量,也不影响血小板功能。

核心结论

  • 新型PDE-3抑制剂物质V独立于血小板功能保护小鼠免于缺血性卒中。

研究设计与样本

  • 在6至8周龄雄性C57Bl/6野生型小鼠中,采用短暂性大脑中动脉闭塞诱导局灶性脑缺血,缺血诱导后1小时给予物质V或溶剂。
  • 在第1天至第7天评估梗死体积和功能结局,并用磁共振成像验证。
  • 检测血脑屏障损伤、局部炎症反应程度和细胞死亡。

主要发现

  • 物质V药理学抑制PDE-3显著减少实验性脑缺血后第1天和第7天的梗死体积并改善神经功能结局。
  • 物质V减轻血脑屏障损伤、减轻脑组织炎症并减少局部细胞死亡。
  • PDE-3抑制剂治疗既不增加脑内出血数量,也不影响血小板功能。

临床怎么用

  • PDE-3抑制剂可能通过抑制血栓炎症机制和稳定血脑屏障成为治疗缺血性卒中的潜在途径。

局限性

  • 研究仅在小鼠模型中进行,尚未在人体中验证。
  • 原文未报告样本量、具体效应值或统计显著性指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Acetylsalicylic acid and clopidogrel are the 2 main antithrombotic drugs for secondary prevention in patients with ischemic stroke (IS) without indication for anticoagulation. Because of their limited efficacy and potential side effects, novel antiplatelet agents are urgently needed. Cilostazol, a specific phosphodiesterase (PDE)-3 inhibitor, protected from IS in clinical studies comprising mainly Asian populations. Nevertheless, the detailed mechanistic role of PDE-3 inhibitors in IS pathophysiology is hardly understood. In this project, we analyzed the efficacy and pathophysiologic mechanisms of a novel and only recently described PDE-3 inhibitor (substance V) in a mouse model of focal cerebral ischemia. Methods- Focal cerebral ischemia was induced by transient middle cerebral artery occlusion in 6- to 8-week-old male C57Bl/6 wild-type mice receiving substance V or vehicle 1 hour after ischemia induction. Infarct volumes and functional outcomes were assessed between day 1 and day 7, and findings were validated by magnetic resonance imaging. Blood-brain barrier damage, as well as the extent of local inflammatory response and cell death, was determined. Results- Inhibition of PDE-3 by pharmacological blockade with substance V significantly reduced infarct volumes and improved neurological outcome on day 1 and 7 after experimental cerebral ischemia. Reduced blood-brain barrier damage, attenuated brain tissue inflammation, and decreased local cell death could be identified as potential mechanisms. PDE-3 inhibitor treatment did neither increase the number of intracerebral hemorrhages nor affect platelet function. Conclusions- The novel PDE-3 inhibitor substance V protected mice from IS independent from platelet function. Pharmaceutical inactivation of PDE-3 might become a promising therapeutic approach to combat IS via inhibition of thromboinflammatory mechanisms and stabilization of the blood-brain barrier.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Bieber M, Schuhmann MK, Volz J, et al. Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function. Stroke. 2019. PMID: 30566040. doi:10.1161/STROKEAHA.118.023664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。